LAMICTAL - LAMICTAL ODT - Pediatric Dosing Illustrator for LAMICTAL

Main Page	\|	Healthcare Professionals	\|	Patients & Caregivers

Important Safety Information

Dosing Overview>

Pediatric Dosing

Adjunctive Pediatric Dosing Tool

Adult Adjunctive Dosing>

Converting to Monotherapy in Adults>

Starter Kits>

The Pediatric Dosing Illustrator for LAMICTAL

This interactive Dosing Illustrator can help you initiate LAMICTAL and calculate titration schedules for your pediatric patients ages 2 to 12. It illustrates optimal dosing for LAMICTAL using either scored tablets or chewable dispersible tablets.

The weight-based calculator gives you the advantage of precise dosing in an easy-to-use format. The tool allows you to print patients' personalized dosing schedules.

A customized patient version allows you to give caregivers and patients a printout that includes illustrations of the tablets in each available dosage. Caregivers and patients can then take home an easy-to-follow reference guide that will make them more comfortable with their regimen.

Click here to use the Pediatric Dosing Illustrator for LAMICTAL.

Safety and effectiveness of LAMICTAL and LAMICTAL ODT have not been established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, or 3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.

THE 2004 AAN/AES TREATMENT GUIDELINES

Evidence-based treatment guidelines support the use of LAMICTAL. These guidelines preceded publication of the study supporting the FDA approval of the PGTC seizure indication for LAMICTAL. For more information, click here.

Important Safety Information About LAMICTAL and LAMICTAL ODT

•

LAMICTAL ODT is another form of LAMICTAL.

•

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:

– coadministration with valproate

– exceeding recommended initial dose of LAMICTAL

– exceeding recommended dose escalation of LAMICTAL

•

Benign rashes are also caused by LAMICTAL; however, it is not possible to predict which rashes will prove to be serious or life-threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related (see Boxed Warning in Prescribing Information).

•

Hypersensitivity reaction may be fatal or life-threatening. Early signs of hypersensitivity (eg, fever, lymphadenopathy) may present without rash; if signs present, patient should be evaluated immediately. LAMICTAL should be discontinued if alternate etiology for hypersensitivity signs is not found.

•

Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

•

Acute multiorgan failure has resulted (some cases fatal).

•

Blood dyscrasias (eg, neutropenia, thrombocytopenia, pancytopenia) may result either with or without an associated hypersensitivity syndrome.

•

Antiepileptic drugs, including LAMICTAL ODT, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.

•

Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

•

Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Medication Guide for LAMICTAL^® (lamotrigine) Tablets and LAMICTAL^® ODT™ (lamotrigine) Orally Disintegrating Tablets

Complete Prescribing Information and Medication Guide for LAMICTAL^® (lamotrigine) Tablets and LAMICTAL^® ODT™ (lamotrigine) Orally Disintegrating Tablets including Boxed Warning